AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway

Journal of Cellular Physiology
Minda ZhangRong Hu

Abstract

The human absent in melanoma 2 (AIM2) is considered as a DNA recognizer. AIM2 has been described as a tumor suppressor gene in the early years. But recent studies suggested that it functions as an oncogene in several cancers. However, its roles in non-small-cell lung cancer (NSCLC) remain unclear. Here we reported that AIM2 highly expressed in NSCLC cells and exhibited a tumor-promoting property both in vitro and in vivo. Besides, AIM2 short hairpin RNA (shRNA)-mediated suppression of cell proliferation was triggered by the accumulation of cells at the G2/M phase. Knockdown of AIM2 reduced the inflammasome formation, while overexpression of AIM2 or stimulation by poly(dA:dT) induced the inflammasome formation. Interestingly, blockade of the inflammasome by caspase-1 inhibitor VX-765 or ASC small interfering RNA (siRNA) abolished the effects brought by AIM2 shRNA and AIM2 plasmid. In summary, our results revealed that AIM2 functioned as an oncogene in NSCLC in an inflammasome-dependent way.

References

Nov 30, 1990·Cell·M J SolomonM W Kirschner
Jan 15, 2005·Biochemical and Biophysical Research Communications·Mario AlbrechtThomas Lengauer
Mar 1, 2005·Oncogene·Daniel J DauerEric B Haura
Apr 12, 2008·Expert Review of Anticancer Therapy·Eric A Engels
Sep 26, 2008·The New England Journal of Medicine·Roy S HerbstScott M Lippman
Oct 9, 2008·Nature Medicine·A McGarry HoughtonSteven D Shapiro
Jan 23, 2009·Nature·Teresa Fernandes-AlnemriEmad S Alnemri
Jan 23, 2009·Nature Immunology·Tilmann BürckstümmerGiulio Superti-Furga
Oct 2, 2009·International Journal of Cancer. Journal International Du Cancer·Georgios PatsosSusanne Dihlmann
Mar 2, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Divaker ChoubeyRatika Srivastava
May 19, 2011·Expert Opinion on Therapeutic Targets·Davide LosaSophie Crespin
Jul 15, 2011·Expert Opinion on Therapeutic Targets·William Cs ChoJoseph Sk Au
Mar 6, 2012·Seminars in Cancer Biology·Julia KantermanMichal Baniyash
Jul 19, 2013·Molecular Cancer Research : MCR·Larissa PonomarevaDivaker Choubey
May 27, 2014·Cell·Mohamed Lamkanfi, Vishva M Dixit
Apr 26, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hui KongWeiping Xie
Jun 23, 2015·Cell·Si Ming ManThirumala-Devi Kanneganti
Jan 1, 2014·JAK-STAT·Pranabananda DuttaWillis X Li
Jun 21, 2016·Cell Reports·Allyson G McLoedTimothy S Blackwell
Oct 23, 2016·Cellular and Molecular Life Sciences : CMLS·Divaker Choubey
Jun 23, 2016·Nature Communications·Mathias S DickPetr Broz
Jan 18, 2017·Cancer Immunology Research·Rajendra KarkiThirumala-Devi Kanneganti
Apr 1, 2017·Frontiers in Immunology·Chu Lin, Jun Zhang
May 21, 2017·Oncotarget·Mehdi FarshchianVeli-Matti Kähäri
Dec 17, 2017·Immunological Reviews·Jérôme Lugrin, Fabio Martinon

❮ Previous
Next ❯

Citations

Jun 28, 2019·Journal of Hematology & Oncology·Shengchao XuChunfang Zhang
Jul 28, 2020·Immunological Reviews·Puja KumariVijay A Rathinam
Apr 25, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Tianyu ZhengXu Yan
Jan 30, 2021·International Reviews of Immunology·Rupak Dey SarkarNabendu Biswas
Nov 10, 2020·Mediators of Inflammation·Yong ChenChanghong Xiao
Mar 30, 2021·Signal Transduction and Targeted Therapy·Pian YuXiang Chen
May 21, 2021·Immunity, Inflammation and Disease·Huan ZhuHaijing Wu
Aug 15, 2021·Life Sciences·Archana SharmaMansoor Ali Syed

❮ Previous
Next ❯

Related Concepts